Table 3 Correlation (P value) between baseline DNA measures and clinical parameters in participants with COPD
From: Cell-free DNA levels associate with COPD exacerbations and mortality
| Â | cf-mtDNA copy number (natural log) | cf-nDNA copy number (natural log) | ||
|---|---|---|---|---|
|  | Unadjusted | Adjusted†| Unadjusted | Adjusted†|
Post-bronchodilator FEV1% | 0.03 (0.14) | 0.04 (0.07) | -0.12 (< 0.001) | -0.13 (< 0.001) |
FVC% | 0.05 (0.028) | 0.05 (0.026) | -0.11 (< 0.001) | -0.10 (< 0.001) |
Post-bronchodilator FEV1/FVC | -0.02 (0.26) | -0.01 (0.56) | -0.07 (0.001) | -0.10 (< 0.001) |
GOLD stage | -0.05 (0.025) | -0.06 (0.009) | 012 (< 0.001) | 0.13 (< 0.001) |
BODE index | 0.00 (0.99) | 0.00 (0.95) | 0.15 (< 0.001) | 0.15 (< 0.001) |
SGRQ total score | 0.04 (0.07) | 0.04 (0.09) | 0.12 (< 0.001) | 0.12 (< 0.001) |
Borg scale‡ | 0.18 (< 0.001) | 0.18 (< 0.001) | 0.06 (0.03) | 0.07 (0.029) |
6MWD | -0.03 (0.14) | -0.04 (0.035) | -0.15 (< 0.001) | -0.13 (< 0.001) |
Presence of emphysema§ | 1.05 (0.06) | 1.05 (0.08) | 0.93 (0.13) | 0.94 (0.20) |
No. of prior exacerbations | 0.05 (0.016) | 0.05 (0.031) | 0.06 (0.012) | 0.06 (0.005) |